Novartis: Pipeline, Products, Performance, Potential

Date: March 22, 2011
Pages: 218
Price:
US$ 1,040.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: NFBAA03267AEN
Leaflet:

Download PDF Leaflet

Novartis: Pipeline, Products, Performance, Potential
Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Snapshot Novartis - Oncology leads the way in 2010...

... The oncology division lead sales growth in 2010, and with oncology being a major focus for Novartis this trend is set to continue. Novartis has an extensive oncology pipeline, the largest of its therapeutic areas, with promising compounds such as panobinostat and midostaurin, which could prove to be future growth drivers.

We predict that Diovan and Glivec/Gleevec will continue to demonstrate substantial sales growth within the medium term. In addition, the launch and approval of a selection of products which include Exjade (deferasirox), Xolair (omalizumab), Exforge (valsartan+amlodipine) and Lucentis (ranibizumab), should offset the decline in sales of a number of Novartis' strategic products.

In the longer term, as a research-intensive company which has benefited from the Chiron acquisition, Novartis has a strong pharmaceutical pipeline with a total of 147 projects under development.

But what's in the pipeline? For the full story on Novartis' challenges and opportunities order this important strategic analysis today

This new strategic report provides a detailed analysis of Novartis' competitive position and prospect for the futures. Using primary source information complemented by original 7-year product forecasts and competitive analysis, the report gives a complete and compelling oversight of the company, its products, pipeline and prospects.

Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.
Latest Results

EXECUTIVE SUMMARY

Introduction
Current Financial Position
  Company Performance 2010
  Business Segment Performance
  Geographic Segment Performance
Company Strategy
  Mergers, Acquisitions and Divestitures
  Key Agreements
    Discontinued Agreements
  Research and Development
  Employees
Product Performance Forecasts
Pipeline Analysis
  Discontinued Projects
Conclusions

THERAPEUTIC AREA FOCUS

R&D PIPELINE

CARDIOVASCULAR AND METABOLISM

Marketed Products
  Diovan
  Exforge
  Galvus
  Tekturna
R&D Projects
  LCZ696

ONCOLOGY/HAEMATOLOGY

Marketed Products
  Afinitor
  Exjade
  Femara
  Glivec
  Proleukin
  Sandostatin
  Tasigna
  Zometa
R&D Projects
  AUY299
  Dovitinib
  Lucatumumab
  Midostaurin
  Opaxio
  Panobinostat

NEUROSCIENCE

Marketed Products
Extavia
Comtan
Exelon
Gilenya
R&D Projects
Valdoxan

OPHTHALMICS/DERMATOLOGY/GASTROINTESTINAL/UROLOGY

Marketed Products
  Elidel
  Lucentis
  Wet Age-related Macular Degeneration
  Visudyne
R&D Projects

INFECTIOUS DISEASES/TRANSPLANTATION/IMMUNOLOGY

Marketed Products
  Certican
  Ixiaro
  Menveo
  Sandimmun
  Sebivo
  Ilaris
R&D Projects

ARTHRITIS/BONE

Marketed Products
  Aclasta
R&D Projects
  Secukinumab

RESPIRATORY

Marketed Products
  Foradil
  Onbrez
  Xolair
R&D Projects

APPENDIX 1 - FINANCIAL PERFORMANCE

Full Year Results 2010

APPENDIX 2 - KEY AGREEMENTS

Ablynx
Aires Pharmaceuticals
Alfacell Corporation
Allergan
Alnylam Pharmaceuticals
AlphaVax Inc
Anadys Pharmaceuticals Inc
Antisoma plc
APT Pharmaceuticals
Ardana plc
Array BioPharma
Arrow Therapeutics Ltd
Ascent Therapeutics Inc
Astex Therapeutics Ltd
AstraZeneca
Avanir Pharmaceuticals Corporation
Avalon Pharmaceuticals
Avila Therapeutics
Bausch & Lomb Inc
Beijing Med-Pharm Corp
Broad Institute / Harvard University
Bayer Schering Pharma
Biovail Corporation
BTG
Celgene Corporation
Cell Therapeutics Inc
Cerimon Pharmaceuticals Inc
Clinical Data Inc
CombinatoRx Inc
Conor Medsystems Inc
Cytos Biotechnology AG
Cytopia Ltd
Debiopharm SA
Dynavax Technologies Corp
Elan Corporation plc
Elixir Medical Co
Elixir Pharmaceuticals
Emisphere Technologies Inc
Endo Pharmaceuticals
Epistem Holdings PLC
Evotec AG
FORMA Therapeutics Inc
Galapagos NV
Genelabs Technologies
Genentech
Gilead Sciences Inc
Human Genome Sciences (HGS)
Idenix Pharmaceuticals Inc
Immusol Incorporated
Incyte
Infinity Pharmaceuticals Inc
Intercell AG
IVAX Corporation
Kyorin Pharmaceutical Co Ltd
Lonza Group Ltd
Meda AB
Medarex Inc
Medivir AB
Merck KGaA
Merck & Co
MicroDose Technologies Inc
Mitsubishi Tanabe Pharma Corporation
Molecular Insight Pharmaceuticals Inc (MIP)
MorphoSys AG
MDRNA Inc
Nektar Therapeutics
Nuevolution AS
Ono Pharmaceutical Co Ltd
Opexa Therapeutics
Orexo AB
Orion Corporation
Otsuka
Paratek Pharmaceuticals
Peptimmune Inc
Portola Pharmaceuticals Inc
Proteon Therapeutics Inc
QLT Inc
Quark Pharmaceuticals
Radius Health Inc
Regeneron Pharmaceuticals
Reliant Pharmaceuticals Inc
Saegis Pharmaceuticals Inc
sanofi-aventis
Senju Pharmaceutical Co Ltd
Servier
Sigma-Tau
SGX Pharmaceuticals Inc
SkyePharma PLC
Takeda
Tanox Biosystems Inc/Genentech Inc
TopoTarget AS
UCB
Valley Forge Pharmaceuticals Inc
Vanda Pharmaceuticals
Vectura Group plc/Arakis Ltd
Vernalis plc
Xenon Pharmaceuticals Inc
XOMA Ltd

APPENDIX 3 - INFRASTRUCTURE

Research and Development Facilities
Manufacturing Facilities

APPENDIX 4 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES

Subsidiaries

APPENDIX 5 - PRODUCT INDEX

LIST OF TABLES

Principal Operating Results
Research And Development Expenditure By Business Area
Sales By Business Area
Operating Income By Business Area
Total Assets By Business Area
Employees By Business Area (Year End)
Employees By Geographical Area (Year End)
Major Products, Therapeutic Areas and Sales
Afinitor Sales by Indication (2009-2017)
Tentative ANDA Approvals for Letrozole
FDA ANDA Approvals for Octreotide Acetate
Tasigna Sales by Indication (2009-2017)
Opaxio Sales (2015-2017)
Panobinostat Sales by Indication (2011-2017)
Interferon Beta-1b Sales by Company (2009-2017)
Gilenya Sales (2010-2017)
Xolair Sales by Company (2009-2017)
Major Pharmaceutical Research & Development Facilities
Major Pharmaceutical Production Facilities

LIST OF CHARTS

Capital Expenditure By Business Area, 2010
Research And Development Expenditure By Business Area, 2010
Sales By Business Area
Operating Income By Business Area
Sales By Destination
Employees By Business Area, 2010
Employees By Geographical Area (Year End), 2010
Forecast Sales of Major Products (2009-2017)
Top Selling Products, 2009
Exforge Sales (2009 - 2017)
Galvus Sales (2009 - 2017)
Afinitor Sales (2009-2017)
Exjade Sales (2009-2017)
Glivec/Gleevec Sales (2009-2017)
Sandostatin Sales (2009-2017)
Tasigna Sales (2009-2017)
Zometa Sales (2009-2017)
Midostaurin Sales (2012-2017)
Panobinostat Total Sales (2011-2017)
Interferon Beta-1b Sales by Company (2009-2017)
Entacapone Sales by Company (2009-2017)
Entacapone Sales by Company (2009-2017)
Exelon Sales (2009-2017)
Gilenya Sales (2010-2017)
Lucentis Sales by Company (2009-2017)
Final RADICAL outcomes (24 months)
Sandimmun/Neoral Sales (2009-2017)
Tyzeka Sales (2009-2017)
Aclasta/Reclast Sales (2009-2017)
Novartis' Sales of Foradil (2009-2017)
Onbrez Breezhaler/Arcapta Neohaler Sales (2010-2017)
Sales, Costs and Operating Income
Profitability and Research Ratios
R&D Expenditure and Capital Expenditure
Current Assets, Liabilities and Ratio
Assets, Cash and Liquidity
Employees and Productivity
Skip to top


UCB: Pipeline, Products, Performance, Potential US$ 1,040.00 Jan, 2010 · 82 pages
Biogen Idec: Pipeline, Products, Performance, Potential US$ 1,040.00 Jan, 2010 · 86 pages
Eli Lilly: Pipeline, Products, Performance, Potential US$ 1,040.00 Jan, 2010 · 142 pages
Kyowa Hakko: Pipeline, Products, Performance, Potential US$ 1,040.00 Aug, 2009 · 84 pages

Ask Your Question

Novartis: Pipeline, Products, Performance, Potential
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: